drugset / Trial / NCT05364944
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, single treatment arm, multicenter study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of Debio 4126 in the treatment of participants with Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine tumors (GEP-NETs).
Timeline
- Start
- 2022-05-18
- Primary completion
- 2024-10-29
- Completion
- 2024-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Debio 4126 | Unknown | — | Intramuscular |
| Background | Lanreotide | Other / unclassified | — | Subcutaneous |
| Background | Octreotide | Peptide | — | Intramuscular |